Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: Evidence for lenalidomide–CCI-779 interaction via P-glycoprotein
CC Hofmeister, X Yang, F Pichiorri, P Chen… - Journal of clinical …, 2011 - ascopubs.org
Purpose Multiple myeloma (MM) is an incurable plasma-cell neoplasm for which most
treatments involve a therapeutic agent combined with dexamethasone. The preclinical
combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro
and represents a novel combination in MM. Patients and Methods A phase I clinical trial was
initiated for patients with relapsed myeloma with administration of oral lenalidomide on days
1 to 21 and CCI-779 intravenously once per week during a 28-day cycle. Pharmacokinetic …
treatments involve a therapeutic agent combined with dexamethasone. The preclinical
combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro
and represents a novel combination in MM. Patients and Methods A phase I clinical trial was
initiated for patients with relapsed myeloma with administration of oral lenalidomide on days
1 to 21 and CCI-779 intravenously once per week during a 28-day cycle. Pharmacokinetic …
[HTML][HTML] Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma.
CC Hofmeister, D Benson, YA Efebera, S Farag… - Blood, 2009 - Elsevier
Abstract Abstract 2884 Poster Board II-860 Introduction. Multiple myeloma is an incurable
plasma cell neoplasm for which most treatments involve a therapeutic agent combined with
dexamethasone. Because steroids have been linked to early deaths and many patients are
steroid intolerant, there is a need for novel steroid-free therapeutic combinations. CCI-779
(an ester of sirolimus) inhibits the mammalian target of rapamycin (mTOR), a Ser/Thr kinase
involved in the initiation of mRNA translation. mTOR, a member of the phosphatidylinositide …
plasma cell neoplasm for which most treatments involve a therapeutic agent combined with
dexamethasone. Because steroids have been linked to early deaths and many patients are
steroid intolerant, there is a need for novel steroid-free therapeutic combinations. CCI-779
(an ester of sirolimus) inhibits the mammalian target of rapamycin (mTOR), a Ser/Thr kinase
involved in the initiation of mRNA translation. mTOR, a member of the phosphatidylinositide …
以上显示的是最相近的搜索结果。 查看全部搜索结果